H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 32.65 DKK -0.15% Market Closed
Market Cap: 32.5B DKK

Relative Value

The Relative Value of one HLUN A stock under the Base Case scenario is 49.91 DKK. Compared to the current market price of 32.65 DKK, H Lundbeck A/S is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLUN A Relative Value
Base Case
49.91 DKK
Undervaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
42
vs Industry
61
Median 3Y
1.4
Median 5Y
1.3
Industry
2.7
Forward
1.3
vs History
44
vs Industry
38
Median 3Y
9.5
Median 5Y
9.3
Industry
22.2
vs History
0
vs Industry
39
Median 3Y
6.2
Median 5Y
6.1
Industry
17.2
vs History
37
vs Industry
36
Median 3Y
2.2
Median 5Y
2.2
Industry
23.7
vs History
50
vs Industry
53
Median 3Y
1.3
Median 5Y
1.3
Industry
2.3
vs History
15
vs Industry
50
Median 3Y
1.4
Median 5Y
1.4
Industry
2.8
Forward
1.8
vs History
15
vs Industry
65
Median 3Y
1.8
Median 5Y
1.8
Industry
5.6
vs History
27
vs Industry
40
Median 3Y
7.1
Median 5Y
7
Industry
13.3
Forward
7.1
vs History
35
vs Industry
37
Median 3Y
7.7
Median 5Y
7.7
Industry
16.5
vs History
7
vs Industry
31
Median 3Y
5.9
Median 5Y
5.9
Industry
15.6
vs History
9
vs Industry
25
Median 3Y
6.6
Median 5Y
6.5
Industry
17.9
vs History
67
vs Industry
60
Median 3Y
1
Median 5Y
1
Industry
2

Multiples Across Competitors

HLUN A Competitors Multiples
H Lundbeck A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
32.4B DKK 1.4 9.8 8.4 8.4
US
Eli Lilly and Co
NYSE:LLY
663.9B USD 12.5 48.1 28.5 31
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
424.9B USD 4.7 18.8 14.3 18.8
CH
Roche Holding AG
SIX:ROG
203.6B CHF 3.4 24.6 9.3 10.8
UK
AstraZeneca PLC
LSE:AZN
179.8B GBP 4.3 29.4 113.3 169.4
CH
Novartis AG
SIX:NOVN
192.2B CHF 4.3 17.5 10.5 13.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13 9.5 10.6
US
Merck & Co Inc
NYSE:MRK
211.9B USD 3.3 12.9 8.3 9.9
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.2 13.3 7.5 10.3
P/E Multiple
Earnings Growth PEG
DK
H Lundbeck A/S
CSE:HLUN A
Average P/E: 20.8
9.8
21%
0.5
US
Eli Lilly and Co
NYSE:LLY
48.1
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.8
27%
0.7
CH
Roche Holding AG
SIX:ROG
24.6
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.4
36%
0.8
CH
Novartis AG
SIX:NOVN
17.5
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13
18%
0.7
US
Merck & Co Inc
NYSE:MRK
12.9
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.3
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBITDA: 395.3
8.4
4%
2.1
US
Eli Lilly and Co
NYSE:LLY
28.5
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.3
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.3
10%
11.3
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
13%
0.7
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 701.6
8.4
4%
2.1
US
Eli Lilly and Co
NYSE:LLY
31
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.8
14%
1.3
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.4
23%
7.4
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.9
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1